Literature DB >> 3190785

A retrospective study of antibodies against basement membrane antigens (type IV collagen and laminin) in patients with primary and secondary Raynaud's phenomenon.

A Gabrielli1, M Montroni, S Rupoli, M L Caniglia, F DeLustro, G Danieli.   

Abstract

Antibodies against type IV collagen were detected in the sera of 21% of patients with primary Raynaud's phenomenon (PRP) and 68% of patients with systemic sclerosis. Sera from 25% of the PRP patients and 48% of systemic sclerosis patients displayed antibodies to laminin. Eighty percent of the patients with PRP and antibodies to basement membrane antigens developed additional serologic or clinical manifestations, whereas only 16% of patients with PRP and no anti-basement membrane antibodies developed such manifestations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190785     DOI: 10.1002/art.1780311114

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  10 in total

1.  Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin.

Authors:  Raffaele De Palma; Francesco Del Galdo; Salvatore Lupoli; Paolo Altucci; Gianfranco Abbate; Gabriele Valentini
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

Review 2.  Raynaud's phenomenon: its relevance to scleroderma.

Authors:  J J Belch
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

3.  Antibodies to mouse laminin in patients with systemic sclerosis (scleroderma) recognize galactosyl (alpha 1-3)-galactose epitopes.

Authors:  A Gabrielli; M Candela; A M Ricciatti; M L Caniglia; J Wieslander
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

Review 4.  Basement membranes and autoimmune diseases.

Authors:  Mary H Foster
Journal:  Matrix Biol       Date:  2016-08-02       Impact factor: 11.583

5.  Anti-laminin autoantibodies in collagen vascular diseases: the use of adequate controls in studies of autoimmune responses to laminin.

Authors:  D E Cohen; L D Kaufman; A A Varma; J R Seibold; M Stiller; B L Gruber
Journal:  Ann Rheum Dis       Date:  1994-03       Impact factor: 19.103

6.  Oropharyngeal and esophageal function in scleroderma.

Authors:  A Montesi; A Pesaresi; M L Cavalli; G Ripa; M Candela; A Gabrielli
Journal:  Dysphagia       Date:  1991       Impact factor: 3.438

7.  Anti-collagen antibodies in systemic sclerosis and in primary Raynaud's phenomenon.

Authors:  L Riente; B Marchini; M P Dolcher; A Puccetti; S Bombardieri; P Migliorini
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

8.  Human anti-fibronectin antibodies in systemic lupus erythematosus: occurrence and antigenic specificity.

Authors:  M S Atta; R J Powell; N D Hopkinson; I Todd
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

9.  Severe Primary Raynaud's Disease Treated with Rituximab.

Authors:  Mohammed Shabrawishi; Abdurahman Albeity; Hani Almoallim
Journal:  Case Rep Rheumatol       Date:  2016-08-29

10.  Omics-Based Approach Reveals Complement-Mediated Inflammation in Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS).

Authors:  Morten Blaabjerg; Anne Louise Hemdrup; Lylia Drici; Klemens Ruprecht; Peter Garred; Romana Höftberger; Bjarne W Kristensen; Daniel Kondziella; Tobias Sejbaek; Soren W Hansen; Helle H Nielsen; Pia Jensen; Morten Meyer; Friedemann Paul; Hans Lassmann; Martin R Larsen; Zsolt Illes
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.